Navigation Links
Sentien Biotechnologies Names Richard Ganz as Executive Chairman
Date:5/15/2020

Sentien Biotechnologies, Inc., a clinical-stage biotechnology company developing novel approaches to cell therapy, today announced the appointment of Richard Ganz as Executive Chairman. Mr. Ganz will continue to lead Sentien’s Board of Directors, a role he has filled for the past nine years, as well as work closely with CEO Brian Miller and Sentien’s management team.

Mr. Ganz has more than 30 years of experience in the healthcare industry. His previous roles include Executive-in-Residence for Kairos Venture Investments, Principal of RGA Life Sciences, Chief Operating Officer of Piramal Critical Care, a global pharmaceutical company; President and Chief Executive Officer at Omnisonics Medical Technologies; President of the North American Renal Division for Baxter International, Inc; and Divisional Vice President and General Manager of Vascular Products at Abbott Laboratories.

“We are very pleased that Mr. Ganz has expanded his leadership role with Sentien,” said Sentien CEO, Brian Miller. “His breadth of experience across several areas of the healthcare industry as well as his depth of knowledge in the critical care disease space has made him an invaluable member of our board. Through this new expanded capacity, Mr. Ganz will provide further strategic leadership as we fundraise for clinical expansion for COVID-19.”

“I am very excited to be expanding my role with Sentien’s leadership team as Executive Chairman,” said Mr. Ganz. “While serving as chairman of the board, I have witnessed Sentien’s rapid growth into a clinical-stage company and I continue to believe strongly in the potential of Sentien’s technology to treat systemic inflammatory diseases. I look forward to contributing to the company’s continued growth in this expanded capacity.”

About Sentien Biotechnologies

Sentien Biotechnologies, Inc. is a privately-held, clinical-stage company developing novel ex-vivo cell therapy applications to treat conditions caused by systemic, immune-mediated inflammation. Sentien’s lead product, SBI-101, integrates allogeneic mesenchymal stromal cells (MSCs) within an extracorporeal, hollow-fiber device. By immobilizing MSCs within a blood-filtration device, SBI-101 allows for prolonged exposure of patient blood to the MSCs, resulting in the dynamic delivery of MSC-secreted factors at doses that are unattainable by direct injection.

SBI-101 is being evaluated in Phase 1b/2a study in subjects with dialysis-requiring acute kidney injury (AKI-D). An interim readout from the clinical study provides evidence of anti-inflammatory and wound healing effects consistent with the SBI-101 therapeutic hypothesis. Building on this therapeutic hypothesis, SBI-101 is being pursued in COVID-19 patients suffering from severe systemic inflammation.

Sentien’s technology can be applied to additional systemic inflammatory indications in both acute and chronic diseases, focusing on complex diseases where single-factor agents have not been effective.

For more information, please visit http://www.sentienbiotech.com.

Read the full story at https://www.prweb.com/releases/sentien_biotechnologies_names_richard_ganz_as_executive_chairman/prweb17120746.htm.


'/>"/>
Source: PRWeb
Copyright©2020 Vocus, Inc.
All rights reserved


Related biology technology :

1. Portage Invests in Sentien Biotechnologies Inc.
2. Sentien Biotechnologies, Inc. Announces Open Enrollment in Phase 1/2 Trial of SBI-101 for Patients with Acute Kidney Injury
3. Adaptive Biotechnologies Signs Biomarker Discovery Collaboration Agreement with Bristol-Myers Squibb
4. TriLink BioTechnologies Announces Worldwide License with QuantiBact A/S, Copenhagen, Denmark
5. Dr. Gerald Jerry Zon Launches New Blog for TriLink BioTechnologies
6. Microvi Biotechnologies Appoints Former COO of Zenon Environmental as Chairman of Board of Directors
7. Adaptive Biotechnologies Receives $2.53 million Phase II SBIR to Develop Test to Identify Cancer Patients at Risk of Death by Infection after Cord Blood Transplants
8. Adaptive Biotechnologies Publishes Gold Standard Method for Sequencing Cells of the Adaptive Immune System
9. Adaptive Biotechnologies and Collaborators Present 16 Studies Demonstrating Clinical Significance of ImmunoSequencing at 55th Annual Meeting of the American Society for Hematology
10. The Adult Stem Cell Technology Center, LLC Launches A Marketing Campaign To License Adult Stem Cell Biotechnologies
11. CORD:USE is Pleased to Announce it has Partnered with Tianhe Stem Cell Biotechnologies, Developer of Cord Blood Stem Cell Therapy Showing Promising Results in Clinical Trials for the Treatment of Diabetes and Autoimmune Diseases
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/31/2020)... WILMINGTON, Del. (PRWEB) , ... August 29, 2020 ... ... of a new Animal Nutrition manufacturing capability in Wuxi, China. The new plant ... DuPont’s global quality standards and advanced technology. , “This facility will improve ...
(Date:8/12/2020)... ... August 12, 2020 , ... ... (EMMA International), a global leader in FDA compliance consulting has been named on ... private companies. The list represents a unique look at the most successful companies ...
(Date:7/31/2020)... ... July 29, 2020 , ... G-CON Manufacturing, the ... new tagline, “BUILDING FOR LIFE.” The adoption of this taglines comes at a ... fast track capacity to provide patients with urgently needed vaccines and other lifesaving ...
(Date:7/31/2020)... MIAMI (PRWEB) , ... July 29, 2020 , ... ... nearly 200 of the top radiation centers in 16 countries, has reached its ... years, SDX® is now in routine use at top universities including University of ...
Breaking Biology Technology:
(Date:9/3/2020)... (PRWEB) , ... September 03, 2020 , ... ... world data, today announced that an extensive third-party assessment of the company’s security ... compliant when measured against federal security regulations. The comprehensive evaluation reviewed Litmus’ processes ...
(Date:8/26/2020)... ... August 25, 2020 , ... ... developing novel pharmaceuticals targeting mitochondria, in partnership with Essex Bio-Technology, a bio-pharmaceutical ... pivotal U.S. Phase 3 VISTA-2 study of SkQ1 ophthalmic solution in patients ...
(Date:8/26/2020)... ... 2020 , ... Modality Solutions, a biopharmaceutical cold chain validation engineering ... The list is the most prestigious ranking of the nation’s fastest-growing private companies. Modality ... list, reported three-year revenue growth of 71 percent. , The Inc. 5000 list ...
Breaking Biology News(10 mins):